falsefalse

Advances in MRD Testing for Informed CRC Treatment - Episode 8

Patient Profile: A 52-Year-Old Woman With Colorectal Cancer

, , ,

John L. Marshall, MD, presents the case of a 52-year-old woman with mid-rectal carcinoma, and the panel offers its initial impressions.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Treating Colorectal Cancer: Overview of MRD Testing and ctDNA
    EP. 2: When is MRD Testing Performed in Colorectal Cancer Treatment?
    EP. 3: MRD Testing Platforms in Colorectal Cancer
    EP. 4: Testing for MRD in Colorectal Cancer
    EP. 5: Colorectal Cancer: MRD Testing in the Community Setting
    EP. 6: Practical Considerations in MRD Testing in CRC
    EP. 7: Evolution of MRD Testing in Colorectal Cancer
    Now Viewing
    EP. 8: Patient Profile: A 52-Year-Old Woman With Colorectal Cancer
    EP. 9: Colorectal Cancer: Updates from the GALAXY Arm in CIRCULATE-Japan
    EP. 10: BESPOKE CRC: Study of ctDNA-Guided Therapy in Colorectal Cancer
    EP. 11: Myths Surrounding Liquid Biopsy and ctDNA Testing for MRD
    EP. 12: Patient Profile 2: A 35-Year-Old Man With Oligometastatic Colorectal Cancer
    EP. 13: Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer
    EP. 14: Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer: Part 2
    EP. 15: CIRCULATE-NORTH AMERICA and Barriers to Enrollment
    EP. 16: MRD Testing in CRC: Gaps in our Understanding and Potential Advancements
    EP. 17: Trajectory of CRC Treatment Landscape

    Related Content:

    Advances in MRD Testing for Informed CRC TreatmentGeorgetown Lombardi Comprehensive Cancer CenterFred Hutch Cancer CenterWeill Cornell Medical College Sandra & Edward Meyer Cancer CenterColorectal CancerOncLive Peer Exchange®
    Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM
    Application of Real-World Evidence in Selecting CAR T in R/R MM
    Encorafenib/Cetuximab Plus mFOLFOX6 Provides New SOC for BRAF V600E+ mCRC
    x